unknown
Stage
About
Akribion Therapeutics is developing an RNA-guided, nuclease-based technology for programmable cell depletion; its G-dase® E payload selectively destroys target cells by shredding DNA and RNA only when a guide RNA matches an intracellular RNA sequence. The company is initially targeting HPV-induced oropharyngeal head and neck cancer (OPSCC) and is exploring applications in oncology, autoimmune diseases, fibrosis, and infectious diseases.
Explore Akribion Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.